Hangzhou, China, Oct. 16, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a provider of medical devices in China, operating through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its various Chinese subsidiaries, announced today its intention to implement a reverse stock split of its ordinary shares at a ratio of 1-for-100 (referred to as the “Reverse Stock Split”). Trading of the Company’s Class A ordinary shares on a post-split basis is slated to commence when the market opens on October 21, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the ticker symbol “WOK,” utilizing a new CUSIP number G9767H117.
The Reverse Stock Split received approval from both the Company’s shareholders and its board of directors, and its primary purpose is to re-establish compliance with Nasdaq Marketplace Rule 5550(a)(2), which pertains to maintaining the minimum bid price per share for the Company’s Class A ordinary shares.
Any fractional shares that would otherwise arise from the Reverse Stock Split will be rounded up to the nearest whole share, and no fractional shares will be issued. This Reverse Stock Split will impact all shareholders uniformly and will not alter any shareholder’s proportional ownership in the Company’s outstanding ordinary shares, save for adjustments resulting from the rounding up of fractional shares.
Subsequent to the Reverse Stock Split taking effect, every one hundred Class A ordinary shares of the Company that are issued and outstanding on the effective date will be automatically consolidated into a single Class A ordinary share. Similarly, every one hundred Class B ordinary shares that are issued and outstanding on the effective date will be automatically combined into one Class B ordinary share. These adjustments are expected to reduce the total count of the Company’s outstanding Class A ordinary shares from approximately 96.00 million to approximately 960,000, and the total number of outstanding Class B ordinary shares will decrease from approximately 7.59 million to approximately 76,000.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, operating via its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its affiliates in China, functions as a medical device provider. It specializes in the development and manufacture of Class I and II medical devices, and also markets Class I and II disposable medical devices through its operational subsidiaries within China. The Company boasts a diverse product range encompassing 21 items, including bespoke and multi-functional masks, alongside other medical consumables. All these products have been distributed across 34 provincial-level administrative regions in China, with 15 of them being sold in over 30 countries globally. The Company has obtained several quality-related manufacturing certifications and has successfully registered 17 products with the U.S. Food and Drug Administration, thereby enabling their entry into the U.S. market. For additional details, please visit the Company’s website: .
Forward-Looking Statements
This press release includes forward-looking statements, specifically those made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be recognized by terminology such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these terms or analogous expressions signifying forward-looking statements. Any statements within this press release that do not represent historical facts should be considered forward-looking statements. Such forward-looking statements contained herein are predicated on the Company’s current expectations, estimations, and projections solely as of the date of this release, and are subject to various risks and uncertainties that could lead to actual results differing materially and adversely from those outlined in or suggested by these forward-looking statements. While the Company believes that the expectations conveyed in these forward-looking statements are reasonable, it cannot guarantee their accuracy, and the Company advises investors that actual outcomes may vary substantially from the projected results. Investors are encouraged to examine other factors that might impact its future performance as detailed in the Company’s annual report on Form 20-F and other filings made with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements, except as mandated by law.
For further information, please reach out to:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
